Iambic Therapeutics, Inc. (IAM)
| Market Cap | 729.26M |
| Revenue (ttm) | 18.25M +689.4% |
| Net Income | -94.25M |
| EPS | -4.27 |
| Shares Out | 47.40M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 364,831 |
| Open | 14.87 |
| Previous Close | 14.78 |
| Day's Range | 13.96 - 15.85 |
| 52-Week Range | 9.60 - 25.00 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 27.25 (+77.12%) |
| Est. Earnings | Nov 23, 2026 |
About IAM
Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally. It offers products, such as IAM-1363, a selective HER2 inhibitor; IAM-K1, a KIF18A inhibitor; IAM217 (a KIF18A inhibitor) and IAM-C1, a CDK2/4 inhibitor; and services, including drug discovery platform and molecular superintelligence platform which includes technologies, such as Enchant and NeuralPLexer to design and develop sm... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for IAM stock is "Strong Buy." The 12-month stock price target is $27.25, which is an increase of 77.12% from the latest price.
News
Iambic Therapeutics initiated with a Buy at Jefferies
Jefferies initiated coverage of Iambic Therapeutics (IAM) with a Buy rating and $35 price target The firm said its Buy rating is driven by the notion that the AI platform…
BofA starts Iambic Therapeutics with a Buy, sees 194% upside
As previously reported, BofA initiated coverage of Iambic Therapeutics (IAM) with a Buy rating and $30 price target which represents about 194% upside. Iambic, which uses AI to design new…
Iambic Therapeutics initiated with a Buy at BofA
BofA initiated coverage of Iambic Therapeutics (IAM) with a Buy rating and $30 price target
Iambic Therapeutics initiated with an Overweight at JPMorgan
JPMorgan initiated coverage of Iambic Therapeutics (IAM) with an Overweight rating and $22 price target The firm believes the company is “at a key inflection point.” Iambic’s AI-driven discovery platf...
Iambic Therapeutics initiated with a Buy at Citi
Citi initiated coverage of Iambic Therapeutics (IAM) with a Buy rating and $22 price target The firm views the company as “differentiated” given its ability to use AI to design…
Iambic Therapeutics announces updated clinical data for IAM1363
Iambic Therapeutics (IAM) announced updated clinical data for IAM1363, a selective and brain-penetrant HER2 tyrosine kinase inhibitor, TKI, from its ongoing Phase 1/1b clinical trial. The data, which ...
Cathie Wood’s ARK Investment buys 1.18M shares of Iambic Therapeutics today
21:21 EDT Cathie Wood’s ARK Investment buys 1.18M shares of Iambic Therapeutics (IAM) today
AI Cancer-Fighting Iambic Therapeutics Stock (IAM) Rockets 13% After $150M IPO
Shares in Nvidia ($NVDA)-backed cancer-fighting biotech Iambic Therapeutics ($IAM) soared 13% on its first day of trading following its U.S. IPO. The San Diego, California, company, self-described as ...
Iambic Therapeutics opens at $16.15, IPO priced at $16.00
Iambic Therapeutics (IAM), a clinical-stage life sciences and technology company advancing novel medicines using its AI-driven platform, priced 9.375M shares at $16.00. The deal priced at the midpoint...
Iambic Therapeutics 9.375M share IPO priced at $16.00
JPMorgan, Jefferies, BofA and Citi are acting as joint book running managers for the offering. The deal priced at midpoint of $15.00-$17.00 target range.
Iambic Therapeutics Registration statement: Registration filing
Iambic Therapeutics filed a registration statement on October 8, 2026, providing details about a securities offering with the SEC.
Small molecule biotech Iambic Therapeutics files for a $100 million IPO
Iambic Therapeutics, a Phase 1 biotech using its AI platform to develop small molecule cancer therapies, filed on Monday with the SEC to raise up to $100 million in an initial public offering.
Iambic Therapeutics IPO Registration Document (S-1)
Iambic Therapeutics has filed to go public with an IPO on the NASDAQ